These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1357451)

  • 1. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.
    Lahtinen R; Laakso M; Palva I; Virkkunen P; Elomaa I
    Lancet; 1992 Oct; 340(8827):1049-52. PubMed ID: 1357451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.
    Laakso M; Lahtinen R; Virkkunen P; Elomaa I
    Br J Haematol; 1994 Aug; 87(4):725-9. PubMed ID: 7986713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults.
    McCloskey EV; MacLennan IC; Drayson MT; Chapman C; Dunn J; Kanis JA
    Br J Haematol; 1998 Feb; 100(2):317-25. PubMed ID: 9488619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications.
    Clemens MR; Fessele K; Heim ME
    Ann Hematol; 1993 Mar; 66(3):141-6. PubMed ID: 8471660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of clodronate in multiple myeloma.
    Jantunen E; Lahtinen R; Laakso M
    Leuk Lymphoma; 1995 Oct; 19(3-4):207-11. PubMed ID: 8535211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of clodronate in multiple myeloma.
    Delmas PD
    Bone; 1991; 12 Suppl 1():S31-4. PubMed ID: 1835398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy.
    Merlini G; Parrinello GA; Piccinini L; Crema F; Fiorentini ML; Riccardi A; Pavesi F; Novazzi F; Silingardi V; Ascari E
    Hematol Oncol; 1990; 8(1):23-30. PubMed ID: 2137106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma.
    McCloskey EV; Dunn JA; Kanis JA; MacLennan IC; Drayson MT
    Br J Haematol; 2001 Jun; 113(4):1035-43. PubMed ID: 11442499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study.
    Rotstein S; Glas U; Eriksson M; Pfeiffer P; Hansen J; Söderqvist J; Bandmann U; Strid S
    Eur J Cancer; 1992; 28A(4-5):890-3. PubMed ID: 1388038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates in multiple myeloma.
    Berenson JR
    Cancer; 1997 Oct; 80(8 Suppl):1661-7. PubMed ID: 9362433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
    Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
    J Clin Oncol; 1993 Jan; 11(1):59-65. PubMed ID: 8418243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of painful bone lesions and hypercalcemia.
    Ascari E; Attardo-Parrinello G; Merlini G
    Eur J Haematol Suppl; 1989; 51():135-9. PubMed ID: 2534078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
    Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
    Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of dichloromethylene diphosphonate in metastatic bone disease.
    Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
    N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].
    Powles T; Paterson A; McCloskey E; Schein P; Scheffler B; Tidy A; Ashley S; Smith I; Ottestad L; Kanis J
    Breast Cancer Res; 2006; 8(2):R13. PubMed ID: 16542503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multiple myeloma and bone manifestations. Role of clodronate].
    Bauduer F; Delmer A
    Bull Cancer; 1996 Jul; 83(7):542-7. PubMed ID: 8868941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.